A deal-specific framework for evaluating regulatory compliance, prescriber dependency, revenue quality, and facility risk before acquiring a compounding pharmacy.
Acquiring a compounding pharmacy involves layers of complexity that standard business acquisitions do not. Beyond financial performance, buyers must assess USP 795/797/800 compliance, state board licensure history, FDA correspondence, cleanroom infrastructure, and the transferability of prescriber referral relationships that often drive the majority of revenue. This checklist organizes the 20 most critical due diligence items into five categories, each calibrated to the specific risks and value drivers of lower middle market compounding pharmacy transactions ranging from $1M to $5M in revenue.
Verify that the pharmacy holds all required licenses and has a clean regulatory history with no outstanding citations, consent orders, or FDA observations that could disrupt operations post-closing.
Obtain and review the current state pharmacy board license, renewal history, and any disciplinary actions or consent orders on record.
A suspended or restricted license can halt operations immediately after closing, destroying deal value.
Red flag: Any active consent order, probationary status, or unresolved disciplinary action with the state board.
Request all FDA 483 observation letters, warning letters, and any import alerts issued in the past five years.
FDA enforcement actions can trigger mandatory shutdowns and are difficult to remediate quickly.
Red flag: An unresolved FDA warning letter or history of repeat 483 observations for the same deficiencies.
Confirm PCAB accreditation status and review the most recent accreditation survey report and corrective action log.
PCAB accreditation signals quality operations and supports valuation; lapses signal compliance weakness.
Red flag: Accreditation lapsed, suspended, or never obtained with no documented compliance roadmap.
Verify DEA registration, controlled substance handling logs, and any DEA inspection history or audit findings.
DEA non-compliance can result in license revocation and criminal liability for the acquiring owner.
Red flag: Missing DEA registration, suspicious order logs, or any prior DEA administrative action on file.
Evaluate the physical compounding environment against USP 795, 797, and 800 standards, including cleanroom certifications, HVAC validation, and hazardous drug handling infrastructure.
Review third-party cleanroom certification reports including ISO classification, particle counts, and HVAC pressure differential testing.
Non-compliant cleanrooms require costly remediation and may trigger regulatory shutdowns before use.
Red flag: Certifications expired over 12 months ago or particle counts consistently exceeding ISO class thresholds.
Assess USP 800 hazardous drug containment infrastructure including negative pressure rooms, biological safety cabinets, and closed-system transfer devices.
USP 800 compliance is now mandatory; non-compliant facilities face enforcement and costly capital upgrades.
Red flag: No negative pressure anteroom or documented hazardous drug handling program for chemotherapy compounds.
Obtain all equipment calibration and preventive maintenance records for laminar flow hoods, balances, autoclaves, and refrigeration units.
Failed or uncalibrated equipment produces out-of-spec compounds and creates patient safety liability.
Red flag: Calibration records missing for more than one critical piece of compounding equipment.
Review beyond-use dating policies and supporting stability data or literature references for top compounded formulations.
Unsupported BUD assignments expose the pharmacy to recalls, liability claims, and regulatory sanctions.
Red flag: BUD policies not grounded in USP guidelines or lacking any supporting stability documentation.
Analyze three years of financial statements, SDE calculations, revenue concentration, and payer mix to validate sustainable cash flow and identify post-closing revenue risk.
Request three years of profit and loss statements, tax returns, and a detailed SDE bridge with all owner add-backs clearly documented.
Inflated SDE from undisclosed add-backs overstates purchase price and distorts return on investment.
Red flag: SDE add-backs exceeding 30% of EBITDA without clear, verifiable supporting documentation.
Analyze revenue breakdown by formulation type including sterile injectables, non-sterile topicals, oral dosage forms, and veterinary compounds.
Sterile compounding commands higher margins but carries greater regulatory and liability exposure.
Red flag: More than 60% of revenue concentrated in sterile formulations without PCAB accreditation or recent 797 certification.
Review payer mix including cash-pay percentage, insurance reimbursement, and any pending third-party payer audits or reimbursement clawbacks.
Insurance audits and retroactive clawbacks can significantly reduce trailing revenue used to set purchase price.
Red flag: Active third-party payer audit, prior clawback exceeding $50K, or PBM contract termination in the past 24 months.
Identify the top 10 compounded formulations by revenue and assess margin per compound after materials, labor, and overhead allocation.
Low-margin commodity compounds dilute overall profitability and may not justify acquisition premium.
Red flag: Top formulation margins below 40% gross or significant revenue from single-source ingredients with supply chain risk.
Assess the depth, diversity, and transferability of the prescriber referral base that drives patient volume, and identify concentration risk that could erode revenue post-acquisition.
Request a prescriber-level revenue report showing each referring physician's contribution as a percentage of total annual revenue.
Heavy dependence on one or two prescribers creates a revenue cliff if those relationships do not transfer.
Red flag: Any single prescriber accounting for more than 25% of annual revenue with no signed referral agreement.
Verify that top prescribers are actively practicing, not approaching retirement, and have no pending board actions or Medicare exclusions.
A retiring or excluded prescriber can eliminate a material revenue stream within months of closing.
Red flag: Top referring physician over age 65 with no documented succession plan or associate covering their patient panel.
Assess the owner's role in maintaining prescriber relationships versus relationship ownership by employed staff pharmacists or sales personnel.
Owner-dependent referrals rarely transfer; staff-owned relationships are more durable through ownership change.
Red flag: Owner personally handles all prescriber outreach with no staff pharmacist or liaison managing referral relationships.
Review any existing prescriber agreements, preferred provider arrangements, or exclusivity understandings with key referring practices.
Undisclosed exclusivity arrangements may restrict the buyer's ability to expand the prescriber network post-closing.
Red flag: Verbal exclusivity commitments to prescribers not disclosed in seller representations, discovered during reference calls.
Evaluate whether the pharmacy can operate independently of the current owner, with documented compounding procedures, a qualified pharmacist-in-charge, and a stable compounding staff.
Confirm the pharmacist-in-charge licensure status and assess whether the PIC will remain post-closing or if a replacement must be identified before closing.
A pharmacy cannot legally operate without a licensed PIC; gaps create immediate regulatory and operational risk.
Red flag: Seller is the sole licensed PIC with no identified successor and no transition period included in the deal structure.
Review master formulation records, SOPs for all compounding processes, and quality assurance documentation including batch records and complaint logs.
Undocumented processes create patient safety risk, regulatory exposure, and operational disruption post-closing.
Red flag: No written master formulation records for top compounds or quality logs maintained only in the owner's personal files.
Assess compounding staff tenure, licensure, and training certifications including USP 797/800 competency assessments and aseptic technique validations.
Losing trained compounding technicians post-closing can disrupt production capacity and trigger compliance gaps.
Red flag: More than 50% of compounding staff with less than one year of tenure or key technicians verbally planning to leave.
Evaluate vendor relationships for active pharmaceutical ingredients, packaging, and lab testing services including supplier qualification documentation.
Single-source API suppliers or unqualified vendors create supply chain risk and potential regulatory non-compliance.
Red flag: Primary API supplier not on FDA drug master file or lacking a signed supplier qualification agreement on file.
Find Compounding Pharmacy Businesses For Sale
Vetted targets with diligence packages — skip the cold search.
Yes. Most states require the buyer to hold an active pharmacist license or designate a licensed pharmacist-in-charge before the state board will approve a change of ownership. Some states allow non-pharmacist investors to own a pharmacy entity, but a licensed PIC must be in place before or at closing. Confirm your target state's ownership rules with a healthcare attorney early in the process, as timelines for PIC approval can add 60 to 90 days to closing.
Focus on three standards: USP 795 governs non-sterile compounding and requires documented formulation records and stability policies; USP 797 governs sterile compounding and mandates ISO-classified cleanrooms, environmental monitoring, and aseptic technique validation; USP 800 governs hazardous drug handling and requires containment engineering controls for any pharmacy compounding chemotherapy or hazardous APIs. Request third-party certification reports for each applicable standard and confirm no corrective actions are outstanding from the most recent survey.
Start by requesting a prescriber-level revenue report to identify concentration risk. Then evaluate whether the relationships are owned by the seller personally or by staff pharmacists and liaisons who will remain post-closing. Structure the deal with an earnout tied to prescriber retention for 12 to 24 months post-closing, and negotiate seller involvement in formal prescriber introductions as a condition of closing. Relationships built on clinical expertise and personalized service typically transfer better than those built on personal friendship.
The most common structure for lower middle market compounding pharmacy acquisitions is a full asset purchase financed with an SBA 7(a) loan covering 75 to 80 percent of the purchase price, a seller note of 10 to 15 percent, and an earnout of 5 to 15 percent tied to prescriber retention or revenue targets over 12 to 24 months post-closing. The asset structure allows the buyer to step up the tax basis of equipment and intangibles. SBA lenders will typically require the buyer to demonstrate pharmacy operational experience or have a qualified PIC identified at underwriting.
More Compounding Pharmacy Guides
More Due Diligence Checklists
Stop cold-searching. Find signal-scored Compounding Pharmacy targets with seller motivation already identified.
Create your free accountNo credit card required
For Buyers
For Sellers